KRAKOW, Poland, Nove. 6, 2019 Ryvu Therapeutics (WSE:
RVU), a clinical-stage biopharmaceutical company developing novel
small molecule therapies that address emerging targets in oncology,
today announced that two abstracts have been accepted for
presentation at the 61st American Society of Hematology (ASH)
Annual Meeting in Orlando, FL,
taking place from December 7-10,
2019.
Details of the poster presentations are as follows:
Poster Presentation: SEL120 – a First-in-Class CDK8/19
Inhibitor As a Novel Option for the Treatment of Acute Myeloid
Leukemia and High-Risk Myelodysplastic Syndrome - Data from
Preclinical Studies and Introduction to a Phase Ib Clinical
Trial
Abstract Number: 2651
Session: 616. Acute Myeloid Leukemia: Novel Therapy,
excluding Transplantation: Poster II
Date: Sunday, December 8,
2019
Time: 6:00 p.m. –
8:00 p.m. PST
Location: Orange County
Convention Center, Hall B
Poster Presentation: CDK8 Inhibitors Induce
Transcriptional Reprogramming of AML Cells Associated with
Differentiation
Abstract Number: 3774
Session: 602. Disordered Gene Expression in Hematologic
Malignancy, including Disordered Epigenetic Regulation: Poster
III
Date: Monday, December 9,
2019
Time: 6:00 p.m. –
8:00 p.m. PST
Location: Orange County
Convention Center, Hall B
To view these abstracts, please visit the American Society of
Hematology website located at
http://www.hematology.org/Annual-Meeting/Abstracts.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical stage biopharmaceutical company
developing novel small molecule therapies that address emerging
targets in oncology. Pipeline candidates make use of diverse
therapeutic mechanisms driven by emerging knowledge of cancer
biology, including small molecules directed at kinase, synthetic
lethality, immuno-oncology and cancer metabolism targets. SEL120 is
a selective CDK8 kinase inhibitor with potential for the treatment
of hematological malignancies and solid tumors currently in
clinical development for the treatment of acute myeloid leukemia
and myelodysplastic syndrome. SEL24/MEN1703 is a dual PIM/FLT3
kinase inhibitor licensed to the Menarini Group in clinical
development for the treatment of acute myeloid leukemia.
For more information, please see www.ryvu.com.
View original
content:http://www.prnewswire.com/news-releases/ryvu-therapeutics-announces-presentations-on-cdk8-inhibitor-sel120-at-the-61st-ash-annual-meeting-300953013.html
SOURCE Ryvu Therapeutics S.A.